[EN] SELECTIVE NR2B ANTAGONISTS<br/>[FR] ANTAGONISTES SÉLECTIFS DE NR2B
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2017066366A1
公开(公告)日:2017-04-20
The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY
申请人:BYLOCK Lars Anders
公开号:US20130236468A1
公开(公告)日:2013-09-12
The present invention relates to a combination comprising compounds of formula (I):
wherein R
1
to R
3
, A, X and n are as defined herein, and an additional active agent. The present invention also relates to pharmaceutical compositions comprising these combinations, and methods of using these combinations to treat various diseases and disorders.